Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID C LARSEN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1679548564
CMS profile
76194
Location
SALT LAKE CITY, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,158.00

75 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,158.00 75

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID C LARSEN

NPI 1679548564 · CMS profile ID 76194

Allopathic & Osteopathic Physicians / Family Medicine

SALT LAKE CITY, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679548564?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID C LARSEN, NPI 1679548564, CMS profile ID 76194. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679548564?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). DAVID C LARSEN, NPI 1679548564, CMS profile ID 76194. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679548564?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
DAVID C LARSEN, NPI 1679548564, CMS profile ID 76194, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1679548564?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

75 matching records · $1,158.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 75 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–75 of 75.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $29.7704/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997728543 CMS
GlaxoSmithKline, LLC. $13.0704/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002190423 CMS
IDORSIA PHARMACEUTICALS US INC $12.3704/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034526965 CMS
PFIZER INC. $1.4204/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050369371 CMS
PFIZER INC. $8.8904/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050435831 CMS
Abbott Laboratories $22.4103/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018481619 CMS
AstraZeneca Pharmaceuticals LP $16.5403/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015907541 CMS
Lilly USA, LLC $14.2803/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031366101 CMS
IDORSIA PHARMACEUTICALS US INC $13.9603/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034526959 CMS
SANOFI-AVENTIS U.S. LLC $15.4703/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049845417 CMS
Amgen Inc. $19.0103/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019884983 CMS
Amgen Inc. $20.2002/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019884989 CMS
PFIZER INC. $13.5902/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050531773 CMS
IDORSIA PHARMACEUTICALS US INC $14.3502/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034526953 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.4302/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996611099 CMS
Dynavax Technologies Corporation $11.3502/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 985815271 CMS
Lilly USA, LLC $16.0901/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031366103 CMS
IDORSIA PHARMACEUTICALS US INC $14.4701/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034526947 CMS
ABBVIE INC. $24.5601/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997728541 CMS
SANOFI-AVENTIS U.S. LLC $14.4701/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049845405 CMS
Lilly USA, LLC $14.5901/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031435685 CMS
GlaxoSmithKline, LLC. $16.8101/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002190445 CMS
ABBVIE INC. $24.4101/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997728539 CMS
IDORSIA PHARMACEUTICALS US INC $13.1501/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034526943 CMS
Novo Nordisk Inc $14.6701/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000220427 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,294.85 91
PY2020 $540.75 39
PY2021 $1,032.78 64
PY2022 $1,029.85 64
PY2023 $1,158.00 75
PY2024 $1,352.92 75
PY2025 $1,170.72 64

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $291,330.97 40
PY2024 Principal investigator $65,366.44 33
PY2023 Recipient $76,562.94 28
PY2023 Principal investigator $214,146.28 67
PY2022 Principal investigator $471,374.64 124
PY2021 Principal investigator $166,399.27 32
PY2020 Principal investigator $25,705.83 6
PY2019 Principal investigator $1,840.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

40 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $1,761.08 12/31/2025 Non-covered Recipient Entity
Wasatch Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228726030
Principal investigator 1 PFIZER INC. $250.00 12/24/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228726464
Principal investigator 1 PFIZER INC. $1,091.02 11/26/2025 Non-covered Recipient Entity
Wasatch Clinical Research LLC
A PHASE 1 MULTICENTER OPENLABEL SINGLEDOSE STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF ZAVEGEPANT IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH HISTORY OF MIGRAINE No dispute reported 06/30/2026 1228716081
Principal investigator 1 PFIZER INC. $130.00 11/26/2025 Non-covered Recipient Entity
Wasatch Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228737458
Principal investigator 1 PFIZER INC. $1,464.08 11/25/2025 Non-covered Recipient Entity
Wasatch Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228738372
Principal investigator 1 PFIZER INC. $5,374.55 11/24/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228728027
Principal investigator 1 PFIZER INC. $300.00 11/24/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228729167
Principal investigator 1 PFIZER INC. $5,347.81 11/20/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228729163
Principal investigator 1 PFIZER INC. $1,464.08 11/04/2025 Non-covered Recipient Entity
Wasatch Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228730012
Principal investigator 1 PFIZER INC. $3,659.48 10/15/2025 Non-covered Recipient Entity
Wasatch Clinical Research LLC
A PHASE 1 MULTICENTER OPENLABEL SINGLEDOSE STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF ZAVEGEPANT IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH HISTORY OF MIGRAINE No dispute reported 06/30/2026 1228722676
Principal investigator 1 PFIZER INC. $1,374.31 10/08/2025 Non-covered Recipient Entity
Wasatch Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228754781
Principal investigator 1 PFIZER INC. $12,430.22 09/26/2025 Non-covered Recipient Entity
Wasatch Clinical Research LLC
A PHASE 1 MULTICENTER OPENLABEL SINGLEDOSE STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF ZAVEGEPANT IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH HISTORY OF MIGRAINE No dispute reported 06/30/2026 1228757936
Principal investigator 1 PFIZER INC. $1,385.10 09/24/2025 Non-covered Recipient Entity
Wasatch Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228761430
Principal investigator 1 PFIZER INC. $150.00 09/11/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228742193
Principal investigator 1 PFIZER INC. $591.85 09/04/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228742875
Principal investigator 1 PFIZER INC. $824.60 09/04/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228742878
Principal investigator 1 American Regent $169,650.80 09/03/2025 Non-covered Recipient Entity
Wasatch Clinical Research
TPX-100 No dispute reported 06/30/2026 1232690005
Principal investigator 1 PFIZER INC. $1,478.93 09/03/2025 Non-covered Recipient Entity
Wasatch Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228750513
Principal investigator 1 PFIZER INC. $6,232.00 08/27/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228753733
Principal investigator 1 PFIZER INC. $600.00 08/19/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228751315
Principal investigator 1 PFIZER INC. $1,478.93 08/02/2025 Non-covered Recipient Entity
Wasatch Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228768043
Principal investigator 1 PFIZER INC. $20,427.72 07/29/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228722784
Principal investigator 1 PFIZER INC. $900.00 07/25/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228766895
Principal investigator 1 PFIZER INC. $1,135.35 07/11/2025 Non-covered Recipient Entity
Wasatch Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228762658
Principal investigator 1 PFIZER INC. $11,037.00 06/26/2025 Non-covered Recipient Entity
Wasatch Clinical Research LLC
A PHASE 1 MULTICENTER OPENLABEL SINGLEDOSE STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF ZAVEGEPANT IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH HISTORY OF MIGRAINE No dispute reported 06/30/2026 1228776379
Principal investigator 1 PFIZER INC. $5,653.81 06/26/2025 Non-covered Recipient Entity
Wasatch Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228778586
Principal investigator 1 PFIZER INC. $150.00 06/19/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228774731
Principal investigator 1 PFIZER INC. $8,048.74 06/13/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228722920
Principal investigator 1 PFIZER INC. $1,000.00 06/05/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228774662
Principal investigator 1 PFIZER INC. $1,897.00 06/05/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228774750
Principal investigator 1 PFIZER INC. $102.00 06/05/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228774875
Principal investigator 1 PFIZER INC. $150.00 06/05/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228775683
Principal investigator 1 PFIZER INC. $3,291.93 04/24/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228763737
Principal investigator 1 PFIZER INC. $618.54 04/04/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228763409
Principal investigator 1 PFIZER INC. $945.31 03/13/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228765874
Principal investigator 1 PFIZER INC. $2,358.58 03/13/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228767620
Principal investigator 1 PFIZER INC. $5,288.00 02/14/2025 Non-covered Recipient Entity
Wasatch Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228770939
Principal investigator 1 PFIZER INC. $24.00 02/13/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228768417
Principal investigator 1 PFIZER INC. $8,984.49 01/23/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228767624
Principal investigator 1 PFIZER INC. $2,279.66 01/16/2025 Non-covered Recipient Entity
WASATCH CLINICAL RESEARCH LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228767651